Drug Trial News

RSS

PanOptica doses first patient in Phase 1/2 dose-ranging clinical trial of PAN-90806

PanOptica, Inc., a private biopharmaceutical company focused on developing innovative ophthalmology therapies, today announced that the Company has dosed the first patient in a Phase 1/2 dose-ranging clinical trial of PAN-90806, a once-daily topical eye drop formulation of a small-molecule anti-vascular endothelial growth factor (anti-VEGF) for the treatment of neovascular eye diseases.

22 May 2018

Investigational drug offers hope of relief for celiac disease patients exposed to gluten

An investigational new drug offers hope of relief for celiac disease patients who are inadvertently exposed to gluten while on a gluten-free diet.

22 May 2018

Researchers to test two-pronged approach in humans to treat advanced colorectal cancer

For the first time in humans, researchers will test a two-pronged approach to treat advanced stage colorectal cancer, potentially increasing life expectancy.

22 May 2018

Pfizer starts Phase 1/2 study of RSV vaccine candidate in healthy adult volunteers

Pfizer Inc. today announced that it has started a Phase 1/2 trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adult volunteers. RSV is a common respiratory virus that affects the lungs and airways, with significant impact on young children and older adults.

22 May 2018

Clinical trial begins enrollment to test safety of experimental MERS treatments

Enrollment has begun in an early-stage clinical trial testing the safety of two human monoclonal antibodies (mAbs) designed to treat people infected with Middle East respiratory syndrome coronavirus (MERS-CoV).

18 May 2018

Pfizer announces Phase 3 study results of LYRICA Oral Solution CV for pediatric epilepsy patients

Pfizer Inc. announced today positive top-line results of a Phase 3 study examining the use of LYRICA® Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age.

17 May 2018

Alexo Therapeutics marks next significant milestone by initiating ALX148 combination cohorts

Alexo Therapeutics, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced it has initiated ALX148 combination dosing with targeted antibody therapies in its Phase 1 clinical program in patients with advanced solid tumors and lymphoma.

17 May 2018

FDA allows KU Medical Center to begin clinical trial of novel cellular therapy for HR/SR aGvHD

The University of Kansas Medical Center announced that the U.S. Food and Drug Administration has cleared it to begin a first-in-human clinical trial of MSCTC-0010 in patients with de novo high-risk acute or steroid-refractory acute graft-versus-host disease (HR/SR aGvHD).

16 May 2018

Study: Drug used to treat blood loss may be beneficial for some stroke patients

Patients with stroke caused by bleeding on the brain may benefit from receiving a drug currently used to treat blood loss from major trauma and bleeding after childbirth, an international trial has revealed.

16 May 2018

UAB-led clinical trial intends to find innovative treatment for multiple myeloma patients

Multiple myeloma is the second most common type of blood cancer in the United States, impacting more than 25,000 people each year and disproportionatly affecting African-American men.

15 May 2018

Phase 1/2 study evaluates safety, tolerability of multiple-ascending doses of ARO-HBV in hepatitis B patients

Arrowhead Pharmaceuticals Inc. today announced that it has dosed the first 3 hepatitis B virus patients in the multiple-ascending dose portion of its ongoing Phase 1/2 study of ARO-HBV, the company's third generation subcutaneously administered RNA interference therapeutic being developed as a potentially curative therapy for patients with chronic HBV infection.

14 May 2018

Aravive Biologics demonstrates proof-of-mechanism for AVB-S6-500 in ongoing phase 1 study

Aravive Biologics, Inc. announced today that the company has demonstrated clinical proof-of-mechanism for AVB-S6-500 in neutralizing GAS6, based on analysis of the single ascending dose portion of the ongoing Phase 1 study.

10 May 2018

Phase 2 study of dexpramipexole in hypereosinophilic syndromes meets its co-primary endpoints

Knopp Biosciences LLC today announced the publication of a report in the journal Blood that a Phase 2 study of dexpramipexole in hypereosinophilic syndromes met its co-primary endpoints.

10 May 2018

Neon Therapeutics evaluates safety, efficacy of NEO-PV-01 in combination with KEYTRUDA and chemotherapy

Neon Therapeutics, a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that it has treated the first patient in a clinical trial evaluating its proprietary personal neoantigen vaccine, NEO-PV-01, in combination with Merck's anti-PD-1 therapy, KEYTRUDA®, along with chemotherapy.

8 May 2018

Phase 2 clinical study of universal influenza vaccine begins in the United States

A Phase 2 clinical trial of an investigational universal influenza vaccine intended to protect against multiple strains of the virus has begun in the United States.

4 May 2018

Sylentis presents clinical study results of new treatment for dry eye syndrome

Sylentis, Pharmaceutical Company belonging to the PharmaMar Group, has presented results from the clinical studies carried out with tivanisiran for the treatment of dry eye syndrome and that has enabled the start-up of the Phase III "Helix" clinical trial.

3 May 2018

Clinical trial tests natural treatment to provide long-term solution for chronic eczema

Eczema is the most common skin disease worldwide. People suffering from it often deal with a lifetime of painful symptoms. A new clinical trial is testing a natural treatment that researchers hope will provide a long-term solution for those dealing with the dry, itchy and painful skin that comes with chronic eczema.

30 Apr 2018

New results reinforce COPAXONE 40 mg/mL as safe and effective for RMS patients

Teva Pharmaceutical Industries Ltd., today announced up to 7-year efficacy, safety and tolerability results from the Glatiramer Acetate Low-Frequency Administration (GALA) open-label extension study of COPAXONE (glatiramer acetate injection) 40 mg/mL administered subcutaneously three-times-a-week for the treatment of relapsing forms of multiple sclerosis (RMS).

28 Apr 2018

New treatment option appears promising for patients with glucocorticoid-induced osteoporosis

About one in every 100 people in the world takes glucocorticoids long term to treat immune-mediated diseases. However, glucocorticoids, such as prednisone, have a side effect -- they induce the bone loss called osteoporosis, causing an estimated yearly bone fracture rate of 5 percent.

27 Apr 2018

New review finds underrepresentation of obese patients in cancer clinical trials

Obesity is a risk factor for a number of cancer types and can influence cancer treatment outcomes. In 2014, cancer types associated with being overweight or obese represented about 40 percent of all cancers diagnosed in the United States.

25 Apr 2018

Drug Trial News

PanOptica doses first patient in Phase 1/2 dose-ranging clinical trial of PAN-90806

Investigational drug offers hope of relief for celiac disease patients exposed to gluten

Researchers to test two-pronged approach in humans to treat advanced colorectal cancer

Pfizer starts Phase 1/2 study of RSV vaccine candidate in healthy adult volunteers

Clinical trial begins enrollment to test safety of experimental MERS treatments

Pfizer announces Phase 3 study results of LYRICA Oral Solution CV for pediatric epilepsy patients

Alexo Therapeutics marks next significant milestone by initiating ALX148 combination cohorts

FDA allows KU Medical Center to begin clinical trial of novel cellular therapy for HR/SR aGvHD

Study: Drug used to treat blood loss may be beneficial for some stroke patients

UAB-led clinical trial intends to find innovative treatment for multiple myeloma patients

Phase 1/2 study evaluates safety, tolerability of multiple-ascending doses of ARO-HBV in hepatitis B patients

Aravive Biologics demonstrates proof-of-mechanism for AVB-S6-500 in ongoing phase 1 study

Phase 2 study of dexpramipexole in hypereosinophilic syndromes meets its co-primary endpoints

Neon Therapeutics evaluates safety, efficacy of NEO-PV-01 in combination with KEYTRUDA and chemotherapy

Phase 2 clinical study of universal influenza vaccine begins in the United States

Sylentis presents clinical study results of new treatment for dry eye syndrome

Clinical trial tests natural treatment to provide long-term solution for chronic eczema

New results reinforce COPAXONE 40 mg/mL as safe and effective for RMS patients

New treatment option appears promising for patients with glucocorticoid-induced osteoporosis

New review finds underrepresentation of obese patients in cancer clinical trials

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News